Close
Help




JOURNAL

Clinical Medicine Insights: Therapeutics

Ceftobiprole: An Emerging Therapeutic Option for Resistant and Complicated Infections

Submit a Paper


Clinical Medicine Insights: Therapeutics 2011:3 57-66

Review

Published on 06 Feb 2011

DOI: 10.4137/CMT.S5032


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Therapeutics

Abstract

Ceftobiprole is a new parenterally administered fifth generation cephalosporin which has been shown to have antimicrobial activity against a broad range of bacteria, and specifically against methicillin-resistant Staphylococcus aureus (MRSA) in complicated skin and skin structure infections (cSSSIs), with a cure rate non-inferior to vancomycin and ceftazidime. It has increased stability against β-lactamases and an increased affinity for PBP2 in MRSA strains. Ceftobiprole has shown a low tendency to select for resistance, and because it is excreted mainly in the urine, a low potential for adverse drug interactions. It has been shown to cause few mild to moderate adverse effects in patients. The broad-spectrum of activity makes it an excellent choice for initial monotherapy in cSSSIs. There is also promise for use in all types of pneumonia, and synergistic possibilities with aminoglycoside and fluoroquinolone drugs. It is awaiting final approval by the FDA.



Downloads

PDF  (529.03 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)




What Your Colleagues Say About Clinical Medicine Insights: Therapeutics
My publishing experience in Clinical Medicine Insights: Therapeutics was great and enjoyable.  The whole process of publication was fast and smooth.  I highly recommend this journal.  Thank you very much and keep up the good work.
Dr Nada Zaki (Universiti Sains Malaysia, Malaysia)
More Testimonials

Quick Links


New article and journal news notification services